This study demonstrates the utility of a transgenic mouse model of breast cancer to define mechanisms of resistance to a pan-HER family inhibitor and identifies a link with EMT. 
Here we show the utility of a genetically engineered mouse model of HER2 driven breast cancer (MMTV-NIC) to define mechanisms of resistance to the pan-HER family inhibitor AZD8931. Genetic manipulation of MMTV-NIC mice demonstrated that loss of PTEN conferred de novo resistance to AZD8931, while a tumour fragment transplantation model was established to assess mechanisms of acquired resistance. Using this approach 50% of tumours developed resistance to AZD8931.
Analysis of the resistant tumours showed two distinct patterns of resistance: tumours in which reduced membranous HER2 expression was associated with an epithelial-tomesenchymal transition (EMT) and resistant tumours that retained HER2 expression and an epithelial morphology. The plasticity of the EMT phenotype was demonstrated upon re-implantation of resistant tumours that then showed a mixed epithelial and mesenchymal phenotype. Further AZD8931 treatment resulted in the generation of secondary resistant tumours that again had either undergone EMT or had retained their original epithelial morphology. The data provide a strong rationale for basing therapeutic decisions on the biology of the individual resistant tumour, which may be very different from that of the primary tumour and will be specific to individual patients.
INTRODUCTION
HER2 (human epidermal growth factor receptor 2) gene amplification and/or protein overexpression occurs in around 20% of breast cancers and is associated with poor prognosis. Several drugs capable of specifically targeting the HER2 pathway have been developed for use in both early and late HER2-positive disease and have had a significant impact on the treatment of HER2-positive breast cancer . These include antibodies directed against HER2 including trastuzumab and pertuzumab, and also small molecule tyrosine kinase inhibitors that target the kinase activity of HER2 and HER1 such as lapatinib. Although initial response rates to the current HER2-targeted therapies are good, resistance is inevitable. Further tyrosine kinase inhibitors including AZD8931 (sapatinib) and neratinib have been developed in an attempt to improve efficacy rates and duration of response. Preclinical studies have identified numerous mechanisms of both de novo and acquired resistance (Creedon et al, 2014; Rexer & Arteaga, 2012) although their clinical validation has been more difficult which reflects the inability of the conventional cell based approaches to adequately model the complexity of the human disease.
The limitation of conventional cell culture and mouse xenograft studies is well recognized as an obstacle to the effective translation of preclinical findings into clinical benefit (Sharpless & Depinho, 2006) . Use of genetically engineered models in which tumours develop in situ in the context of an intact microenvironment is a viable alternative for preclinical assessment of both drug response and mechanisms of resistance (van Miltenburg & Jonkers, 2012) . Generation of autochthonous tumours driven by cell specific expression of oncogenic drivers or loss of tumour suppressors relevant to human tumours gives rise to tumours in which the histopathology and disease progression also recapitulate many aspects of the human disease providing more relevant models with which to study drug response. Here we describe the use of a HER2 driven model of mammary tumourigenesis as a preclinical tool to study response and resistance mechanisms in HER2-positive breast cancer. We have used the MMTV-NIC (Neu-IRES-Cre) model (Ursini-Siegel et al, 2008) , which employs a bicistronic transcript to co-express activated ErbB2/Neu (HER2) with MMTV-Cre recombinase, resulting in the formation of activated ErbB2/Neu driven mammary tumours. The advantage of this model is that the coupling of activated ErbB2/Neu with Cre recombinase in the same cell means that Cre negative tumour cells are not generated allowing the efficient Cre-mediated deletion of additional conditional Disease Models & Mechanisms • DMM • Advance article alleles (Schade et al, 2009 ). This allows validation of potential mechanisms of de novo resistance such as loss of PTEN. Loss of PTEN and subsequent activation of the PI3K pathway has been identified as a key determinant of trastuzumab sensitivity and has been associated with poorer overall survival in trastuzumab treated patients (Berns et al, 2007; Esteva et al, 2010; Nagata et al, 2004) although the impact on lapatinib resistance remains unclear (Xia et al, 2007) . Here we have coupled loss of PTEN with HER2 activation in the MMTV-NIC model and demonstrate that loss of PTEN is associated with de novo resistance to the small molecule tyrosine kinase inhibitor sapatinib (AZD8931). We also show the utility of the model for identifying mechanisms of acquired resistance to HER2 targeted therapy and identify the induction of an epithelial-to-mesenchymal transition (EMT) in a sub-population of AZD8931 resistant tumours.
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RESULTS
Loss of PTEN confers resistance to AZD8931
Initial experiments were carried out to determine whether the MMTV-NIC model was sensitive to the HER family tyrosine kinase inhibitor AZD8931. As loss of PTEN and activation of the PI3K signaling pathway has previously been reported to confer resistance to trastuzumab, cohorts of both MMTV-NIC PTEN +/+ and MMTV-NIC PTEN +/-mice were used. Both MMTV-NIC PTEN +/+ and MMTV-NIC PTEN +/-mice developed on average 4 tumours per mouse with 100% penetrance. As described previously, loss of PTEN accelerated tumour onset in the MMTV-NIC mice (Schade et al, 2009 Fig. 1A ). Western blot analysis of tumours showed reduced expression of PTEN and increased phosphorylation of Akt in tumours taken from the MMTV-NIC PTEN +/-mice consistent with increased signaling through the PI3K pathway ( Supplementary Fig. 1B ).
To assess the response to AZD8931, we randomized cohorts of MMTV-NIC 
Establishment of orthotopic transplanted tumours
The multifocal nature of the MMTV-NIC model means that it is not possible to study mechanisms of acquired drug resistance. We therefore established whether the MMTV-NIC PTEN tumours could be orthotopically transplanted into syngeneic wild type FVB/N mice to provide a more tractable model for drug resistance studies. We Initial studies to determine the suitability of the MMTV-NIC transplantation model for drug efficacy studies were carried out using the taxane paclitaxel whose role in the management of both early and metastatic breast cancer is well established (Gajria et al, 2010; Ghersi et al, 2005) . Paclitaxel treatment resulted in a statistically significant increase in overall survival of mice bearing fragment-derived tumours. Median overall survival was increased from 14 days in vehicle treated animals (range 7-14 days) to 24 days (range 24-24 days) in drug treated animals (p=0.03, Gehan-Breslow Wilcoxon test). Looking at the response of individual tumours to treatment, we found that although paclitaxel slowed tumour growth, it did not result in tumour shrinkage (Fig. 2D ).
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Development of resistance to AZD8931
We next determined whether the MMTV-NIC tumours could be used to model acquired resistance to AZD8931. We generated tumour fragments from 3 separate Histopathological examination of the matched AZD8931 naïve and resistant tumours revealed that although all the AZD8931 naïve tumours were histologically indistinguishable from each other (Fig. 3B , C) there were significant differences in the AZD8931 resistant tumours (Fig. 3D, E) . While some of the resistant tumours had the same histopathological phenotype as their matched naïve tumour (Fig. 3D) , a subset of resistant tumours had a more pleomorphic appearance and were comprised of spindle cells suggestive of tumours under going EMT (Fig. 3E ).
Loss of cell surface E-cadherin is an established marker of EMT and while strong membranous expression of E-cadherin was seen in all drug naïve tumours, loss of Ecadherin in the resistant tumours was associated with the conversion to a spindle cell morphology ( Fig. 4A-D) , with the resistant tumours that had not undergone the morphological change retaining expression of E-cadherin ( Fig. 4I-L ). This loss of Ecadherin was accompanied by expression of the mesenchymal marker vimentin in the resistant spindle cell tumours (Fig. 4E , F) indicating that these resistant tumours have undergone EMT. HER2 expression was preserved in the resistant tumours which had retained the histopathological features of the drug naïve tumours ( Fig. 4O, P ), but total loss of membranous HER2 expression was seen in the resistant spindle cell tumours ( Fig. 4G, H ).
To establish whether the resistant phenotype was stable, fragments from one individual resistant tumour were reimplanted into cohorts of wild type FVB/N mice.
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Following the development of established tumours, mice were randomized to treatment with either vehicle or AZD8931. AZD8931 treatment prevented the growth of one tumour, although tumour regression did not occur (Fig. 5A , red growth curve, "AZD8931 responsive"). The remaining three tumours responded initially to AZD8931, although resistance did develop over time (Fig. 5A , black growth curves, "AZD8931 resistant"). The onset of secondary resistance was faster than in the orginal drug naïve tumour fragments (compare Figs 3A, 5A ).
The vehicle treated tumours were all highly mitotic with rounded cells with pleomorphic nuclei (Fig. 5B) . The tumour whose growth was inhibited by AZD8931 had mild to moderately pleomorphic nuclei and no mitoses (Fig. 5C ). The resistant tumours had distinct morphologies: two of the tumours were comprised of highly mitotic spindle cells with similar histology to those seen in the primary resistant tumours that had undergone EMT (compare Fig. 5E , F and Fig. 3C ), while the remaining resistant tumour had a papillary architecture with moderate/marked nuclear pleomorphism (Fig. 5D) . As we had previously demonstrated a reduction in pAkt and pMAPK following acute treatment with AZD8931 ( Fig. 1F ) we looked at activation of Akt and MAPK following development of resistance to AZD8931 ( Fig. 6G-P) .
Chronic exposure to AZD8931 did not reduce pAkt and pMAPK levels, although one AZD89231 resistant tumour showed an overall reduction in pMAPK staining with only small pockets of pMAPK positive cells scattered throughout the tumour (Fig.   6N ).
Further analysis of the tumours revealed that all vehicle treated tumours expressed both E-cadherin and vimentin (Fig. 6A) . The AZD8931 responsive tumour was also both E-cadherin and vimentin positive although the number of vimentin positive tumour cells was much lower than in the vehicle treated tumours (Fig. 6B) . As with the primary resistant tumours the two spindle cell AZD8931 resistant tumours had lost E-cadherin and were strongly vimentin positive. Strikingly this was associated with loss of membranous HER2 expression (Fig. 6D, E) . The remaining AZD8931 resistant tumour resembled the vehicle treated tumours being both E-cadherin and vimentin positive (Fig. 6C) . Thus the development of resistance to AZD8931 in a sub- in therapeutic response has been previously described in other genetically engineered models (Rottenberg et al, 2007) and contrasts with the more uniform response seen in xenograft studies (Becher & Holland, 2006) . This is an important advance as it enables us to more accurately recapitulate the behaviour of human tumours and is most likely due to the random acquisition of secondary mutations during tumour development and progression in these models. In addition we show for the first time that acquired resistance to a HER2 targeted therapy can be modeled in MMTV-NIC tumours. The majority of studies exploring resistance to HER2 directed therapies have used cell line based approaches and although numerous resistance mechanisms have been identified in vitro, clinical validation has proved challenging. The use of genetically engineered models to explore resistance mechanisms offers a more physiologically relevant system with tumours developing resistance whilst exposed to ongoing in vivo selection pressures. Therefore any resistance strategies identified may be more predictive of clinically relevant resistance mechanisms.
We identified PTEN loss as an important determinant of de novo AZD8931
resistance. Loss of PTEN and subsequent activation of the PI3K pathway has been identified as a key determinant of trastuzumab sensitivity and has been associated with poorer overall survival in trastuzumab treated patients (Berns et al, 2007; Esteva et al, 2010; Nagata et al, 2004) although the impact on lapatinib resistance remains unclear (Xia et al, 2007) . Like lapatinib, AZD8931 is a dual inhibitor of both HER2
and HER1, however, it has a unique profile of activity being a more effective inhibitor of HER family signaling than lapatinib resulting in a distinct profile of antitumour activity (Hickinson et al, 2010) . Current trials are underway to determine conjugates such as trastuzumab-emtansine. As it is rarely mandatory to re-biopsy tumours at the time of entry into clinical trials, patients whose tumours no longer express HER2 risk being exposed to the toxicity of treatments that might not be anticipated to be effective.
Several in vitro studies have shown that resistance to lapatinib and trastuzumab are associated with induction of EMT (Creedon et al, 2014; Kim et al, 2013; Korkaya et al, 2012; Oliveras-Ferraros et al, 2012) One of the main challenges going forward is the identification of effective drug combinations to combat resistance to HER2 targeted therapies. Use of the transplantable tumour model described here provides a powerful preclinical tool with which to test potential novel combinations in resistant tumours, studies which to date rely on use of resistant cell lines established in vitro. For example, exploiting the molecular differences in resistant tumours that have undergone EMT may provide alternative combination strategies for overcoming resistance in these tumours.
MATERIALS AND METHODS
Animals
MMTV-NIC mice expressing an oncogenic ErbB2/Neu allele and Cre recombinase under the control of the MMTV promoter were generated as previously described 
Immunohistochemistry
Immunohistochemistry of formalin-fixed, paraffin-embedded tissues was performed as described previously (Karim et al, 2013) . Primary antibodies used were HER2
(Invitrogen, Cat#AHO1011, 1:1000), pY1221/1222 HER2 (Cat#2243, 1:400), pY1289 HER3 (Cat#4791, 1:100), Ki67 (Vector, Cat#VP-RM04, 1:500), E-cadherin (Cat#3195, 1:5000), vimentin (Cat#5741, 1:100), pS473 Akt (Cat#4060, 1:50) and pT202/Y204 MAPK (Cat#4370, 1:400)(all Cell Signaling, UK).
Western blotting
Western blot analysis was performed as described previously (Karim et al, 2013) .
Primary antibodies used were HER2 (Cat#2248, 1:1000), pS473 Akt (Cat#4060, 1:1000), Akt (Cat#9272, 1:1000), PTEN (Cat#9552, 1:1000) and (all Cell Signaling, UK) and -actin (Cat#A4700, Sigma, UK; 1:5000).
Reverse phase protein array (RPPA) analysis
Tumours were washed with PBS and lysed in 1% Triton X-100, 50 mM HEPES (pH 7.4), 150 mM sodium chloride, 1.5 mM magnesium chloride, 1 mM EGTA, 100 mM sodium fluoride, 10 mM sodium pyrophosphate, 1 mM sodium vanadate, 10%
glycerol, supplemented with cOmplete ULTRA protease inhibitor and PhosSTOP phosphatase inhibitor cocktails (Sigma, UK). Cleared lysates were serially diluted to produce a dilution series comprising four serial two-fold dilutions of each sample, which were spotted onto nitrocellulose-coated slides (Grace Bio-Labs, supplied by was used to read the slides, and images were acquired at the highest gain without saturation of the fluorescence signal. The relative fluorescence intensity of each sample replicate was quantified using Mapix software (Innopsys).
The linear fit of the dilution series of each sample was determined for each primary antibody, from which median relative fluorescence intensities were calculated, and samples with R 2 < 0.8 in all three replicates were excluded. Signal intensities were normalized by global sample median normalization (Guo et al, 2012) . 
Implications and future directions
This study highlights the complexity of resistance mechanisms adopted by small molecule inhibitors by using a mouse transgenic model. The observation that 50% of resistant tumours no longer expressed high levels of membranous HER2 could have a significant impact on future treatments as currently secondary treatments are focused on alternative strategies for targeting HER2 signaling. It is rarely mandatory to rebiopsy tumours at the time of entry into clinical trials, and patients whose tumours no longer express HER2 risk being exposed to the toxicity of treatments that might be anticipated to be ineffective. Furthermore exploiting the molecular differences in The data provide a strong rationale for basing therapeutic decisions on the biology of the individual resistant tumour, which may be very different from that of the primary tumour.
